Management of patients with increased risk for familial pancreatic cancer: Updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium

Michael Goggins, Kasper Alexander Overbeek, Randall Brand, Sapna Syngal, Marco Del Chiaro, Detlef K. Bartsch, Claudio Bassi, Alfredo Carrato, James Farrell, Elliot Fishman, Paul Fockens, Thomas M. Gress, Jeanin E. Van Hooft, R. H. Hruban, Fay Kastrinos, Allison Klein, Anne Marie Lennon, Aimee Lucas, Walter Park, Anil RustgiDiane Simeone, Elena Stoffel, Hans F.A. Vasen, Djuna L. Cahen, Marcia Irene Canto, Marco Bruno

Research output: Contribution to journalArticle

Abstract

Background and aim: The International Cancer of the Pancreas Screening Consortium met in 2018 to update its consensus recommendations for the management of individuals with increased risk of pancreatic cancer based on family history or germline mutation status (high-risk individuals). Methods: A modified Delphi approach was employed to reach consensus among a multidisciplinary group of experts who voted on consensus statements. Consensus was considered reached if ≥75% agreed or disagreed. Results: Consensus was reached on 55 statements. The main goals of surveillance (to identify high-grade dysplastic precursor lesions and T1N0M0 pancreatic cancer) remained unchanged. Experts agreed that for those with familial risk, surveillance should start no earlier than age 50 or 10 years earlier than the youngest relative with pancreatic cancer, but were split on whether to start at age 50 or 55. Germline ATM mutation carriers with one affected first-degree relative are now considered eligible for surveillance. Experts agreed that preferred surveillance tests are endoscopic ultrasound and MRI/magnetic retrograde cholangiopancreatography, but no consensus was reached on how to alternate these modalities. Annual surveillance is recommended in the absence of concerning lesions. Main areas of disagreement included if and how surveillance should be performed for hereditary pancreatitis, and the management of indeterminate lesions. Conclusions: Pancreatic surveillance is recommended for selected high-risk individuals to detect early pancreatic cancer and its high-grade precursors, but should be performed in a research setting by multidisciplinary teams in centres with appropriate expertise. Until more evidence supporting these recommendations is available, the benefits, risks and costs of surveillance of pancreatic surveillance need additional evaluation.

Original languageEnglish (US)
Article number319352
JournalGut
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Pancreatic Neoplasms
Early Detection of Cancer
Consensus
Germ-Line Mutation
Cost-Benefit Analysis
Research

Keywords

  • early detection
  • familial pancreatic cancer
  • genetic predisposition
  • pancreatic ductal adenocarcinoma
  • surveillance

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Management of patients with increased risk for familial pancreatic cancer : Updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. / Goggins, Michael; Overbeek, Kasper Alexander; Brand, Randall; Syngal, Sapna; Del Chiaro, Marco; Bartsch, Detlef K.; Bassi, Claudio; Carrato, Alfredo; Farrell, James; Fishman, Elliot; Fockens, Paul; Gress, Thomas M.; Van Hooft, Jeanin E.; Hruban, R. H.; Kastrinos, Fay; Klein, Allison; Lennon, Anne Marie; Lucas, Aimee; Park, Walter; Rustgi, Anil; Simeone, Diane; Stoffel, Elena; Vasen, Hans F.A.; Cahen, Djuna L.; Canto, Marcia Irene; Bruno, Marco.

In: Gut, 01.01.2019.

Research output: Contribution to journalArticle

Goggins, M, Overbeek, KA, Brand, R, Syngal, S, Del Chiaro, M, Bartsch, DK, Bassi, C, Carrato, A, Farrell, J, Fishman, E, Fockens, P, Gress, TM, Van Hooft, JE, Hruban, RH, Kastrinos, F, Klein, A, Lennon, AM, Lucas, A, Park, W, Rustgi, A, Simeone, D, Stoffel, E, Vasen, HFA, Cahen, DL, Canto, MI & Bruno, M 2019, 'Management of patients with increased risk for familial pancreatic cancer: Updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium', Gut. https://doi.org/10.1136/gutjnl-2019-319352
Goggins, Michael ; Overbeek, Kasper Alexander ; Brand, Randall ; Syngal, Sapna ; Del Chiaro, Marco ; Bartsch, Detlef K. ; Bassi, Claudio ; Carrato, Alfredo ; Farrell, James ; Fishman, Elliot ; Fockens, Paul ; Gress, Thomas M. ; Van Hooft, Jeanin E. ; Hruban, R. H. ; Kastrinos, Fay ; Klein, Allison ; Lennon, Anne Marie ; Lucas, Aimee ; Park, Walter ; Rustgi, Anil ; Simeone, Diane ; Stoffel, Elena ; Vasen, Hans F.A. ; Cahen, Djuna L. ; Canto, Marcia Irene ; Bruno, Marco. / Management of patients with increased risk for familial pancreatic cancer : Updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. In: Gut. 2019.
@article{98ac8b757bcd444ca0f23fe9ea5c33f5,
title = "Management of patients with increased risk for familial pancreatic cancer: Updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium",
abstract = "Background and aim: The International Cancer of the Pancreas Screening Consortium met in 2018 to update its consensus recommendations for the management of individuals with increased risk of pancreatic cancer based on family history or germline mutation status (high-risk individuals). Methods: A modified Delphi approach was employed to reach consensus among a multidisciplinary group of experts who voted on consensus statements. Consensus was considered reached if ≥75{\%} agreed or disagreed. Results: Consensus was reached on 55 statements. The main goals of surveillance (to identify high-grade dysplastic precursor lesions and T1N0M0 pancreatic cancer) remained unchanged. Experts agreed that for those with familial risk, surveillance should start no earlier than age 50 or 10 years earlier than the youngest relative with pancreatic cancer, but were split on whether to start at age 50 or 55. Germline ATM mutation carriers with one affected first-degree relative are now considered eligible for surveillance. Experts agreed that preferred surveillance tests are endoscopic ultrasound and MRI/magnetic retrograde cholangiopancreatography, but no consensus was reached on how to alternate these modalities. Annual surveillance is recommended in the absence of concerning lesions. Main areas of disagreement included if and how surveillance should be performed for hereditary pancreatitis, and the management of indeterminate lesions. Conclusions: Pancreatic surveillance is recommended for selected high-risk individuals to detect early pancreatic cancer and its high-grade precursors, but should be performed in a research setting by multidisciplinary teams in centres with appropriate expertise. Until more evidence supporting these recommendations is available, the benefits, risks and costs of surveillance of pancreatic surveillance need additional evaluation.",
keywords = "early detection, familial pancreatic cancer, genetic predisposition, pancreatic ductal adenocarcinoma, surveillance",
author = "Michael Goggins and Overbeek, {Kasper Alexander} and Randall Brand and Sapna Syngal and {Del Chiaro}, Marco and Bartsch, {Detlef K.} and Claudio Bassi and Alfredo Carrato and James Farrell and Elliot Fishman and Paul Fockens and Gress, {Thomas M.} and {Van Hooft}, {Jeanin E.} and Hruban, {R. H.} and Fay Kastrinos and Allison Klein and Lennon, {Anne Marie} and Aimee Lucas and Walter Park and Anil Rustgi and Diane Simeone and Elena Stoffel and Vasen, {Hans F.A.} and Cahen, {Djuna L.} and Canto, {Marcia Irene} and Marco Bruno",
year = "2019",
month = "1",
day = "1",
doi = "10.1136/gutjnl-2019-319352",
language = "English (US)",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Management of patients with increased risk for familial pancreatic cancer

T2 - Updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium

AU - Goggins, Michael

AU - Overbeek, Kasper Alexander

AU - Brand, Randall

AU - Syngal, Sapna

AU - Del Chiaro, Marco

AU - Bartsch, Detlef K.

AU - Bassi, Claudio

AU - Carrato, Alfredo

AU - Farrell, James

AU - Fishman, Elliot

AU - Fockens, Paul

AU - Gress, Thomas M.

AU - Van Hooft, Jeanin E.

AU - Hruban, R. H.

AU - Kastrinos, Fay

AU - Klein, Allison

AU - Lennon, Anne Marie

AU - Lucas, Aimee

AU - Park, Walter

AU - Rustgi, Anil

AU - Simeone, Diane

AU - Stoffel, Elena

AU - Vasen, Hans F.A.

AU - Cahen, Djuna L.

AU - Canto, Marcia Irene

AU - Bruno, Marco

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background and aim: The International Cancer of the Pancreas Screening Consortium met in 2018 to update its consensus recommendations for the management of individuals with increased risk of pancreatic cancer based on family history or germline mutation status (high-risk individuals). Methods: A modified Delphi approach was employed to reach consensus among a multidisciplinary group of experts who voted on consensus statements. Consensus was considered reached if ≥75% agreed or disagreed. Results: Consensus was reached on 55 statements. The main goals of surveillance (to identify high-grade dysplastic precursor lesions and T1N0M0 pancreatic cancer) remained unchanged. Experts agreed that for those with familial risk, surveillance should start no earlier than age 50 or 10 years earlier than the youngest relative with pancreatic cancer, but were split on whether to start at age 50 or 55. Germline ATM mutation carriers with one affected first-degree relative are now considered eligible for surveillance. Experts agreed that preferred surveillance tests are endoscopic ultrasound and MRI/magnetic retrograde cholangiopancreatography, but no consensus was reached on how to alternate these modalities. Annual surveillance is recommended in the absence of concerning lesions. Main areas of disagreement included if and how surveillance should be performed for hereditary pancreatitis, and the management of indeterminate lesions. Conclusions: Pancreatic surveillance is recommended for selected high-risk individuals to detect early pancreatic cancer and its high-grade precursors, but should be performed in a research setting by multidisciplinary teams in centres with appropriate expertise. Until more evidence supporting these recommendations is available, the benefits, risks and costs of surveillance of pancreatic surveillance need additional evaluation.

AB - Background and aim: The International Cancer of the Pancreas Screening Consortium met in 2018 to update its consensus recommendations for the management of individuals with increased risk of pancreatic cancer based on family history or germline mutation status (high-risk individuals). Methods: A modified Delphi approach was employed to reach consensus among a multidisciplinary group of experts who voted on consensus statements. Consensus was considered reached if ≥75% agreed or disagreed. Results: Consensus was reached on 55 statements. The main goals of surveillance (to identify high-grade dysplastic precursor lesions and T1N0M0 pancreatic cancer) remained unchanged. Experts agreed that for those with familial risk, surveillance should start no earlier than age 50 or 10 years earlier than the youngest relative with pancreatic cancer, but were split on whether to start at age 50 or 55. Germline ATM mutation carriers with one affected first-degree relative are now considered eligible for surveillance. Experts agreed that preferred surveillance tests are endoscopic ultrasound and MRI/magnetic retrograde cholangiopancreatography, but no consensus was reached on how to alternate these modalities. Annual surveillance is recommended in the absence of concerning lesions. Main areas of disagreement included if and how surveillance should be performed for hereditary pancreatitis, and the management of indeterminate lesions. Conclusions: Pancreatic surveillance is recommended for selected high-risk individuals to detect early pancreatic cancer and its high-grade precursors, but should be performed in a research setting by multidisciplinary teams in centres with appropriate expertise. Until more evidence supporting these recommendations is available, the benefits, risks and costs of surveillance of pancreatic surveillance need additional evaluation.

KW - early detection

KW - familial pancreatic cancer

KW - genetic predisposition

KW - pancreatic ductal adenocarcinoma

KW - surveillance

UR - http://www.scopus.com/inward/record.url?scp=85074476875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074476875&partnerID=8YFLogxK

U2 - 10.1136/gutjnl-2019-319352

DO - 10.1136/gutjnl-2019-319352

M3 - Article

C2 - 31672839

AN - SCOPUS:85074476875

JO - Gut

JF - Gut

SN - 0017-5749

M1 - 319352

ER -